Akebia Therapeutics, Inc. is a biopharmaceutical company focused on the development of small molecules for the treatment of anemia and vascular disease. The company’s lead compound, AKB-6548, is a once daily, oral HIF2 stabilizing agent (HIF-PH inhibitor) in phase 2 clinical trials for chronic anemia. Akebia also has a platform of novel HPTPß inhibitors / Angiopoietin 2 modulators which have demonstrated preclinical proof of concept in vascular leak, angiogenesis and as anti-metastatic agents. The first product to be developed from this platform, AKB-9778, is in late-stage preclinical development. Akebia is based in Cincinnati, Ohio, and is backed by a national syndicate of leading investors.